Nemaura Medical Sept. 30 Cash Position Was $1.8M

Second Quarter 2019 Results: Research and development expenses decreased to $462,517 for the quarter ended September 2019, a decrease of $159,765 for the same quarter in 2018. General and

Benzinga · 11/11/2019 14:08

Second Quarter 2019 Results:

  • Research and development expenses decreased to $462,517 for the quarter ended September 2019, a decrease of $159,765 for the same quarter in 2018.
  • General and administrative expenses increased to $654,523 for the quarter ended September 2019, compared with $525,075 for the same quarter in 2018.
  • The Company's comprehensive loss was $1,124,441 for the quarter ended September 2019, compared with $1,177,758 for the same quarter in 2018.
  • At September 30, 2019, the Company's cash balance was $1,771,115. The Company is immediately able to draw down on the first $3.5 million of a Senior Debt Facility provided by investors, which is intended to help fund the Company's European launch of SugarBEAT®.